-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Mydecine (OTC:MYCOF) and Lobe Sciences (OTCQB:LOBEF), two companies in the psychedelics space, have filed patent applications. This is the first step in the process of receiving a patent, which needs to be granted by an overseeing body.
Mydecine's Patent On The MYCO-006 Family Of Compounds
Mydecine is a company developing innovative first- and-second-generation therapeutics for the treatment of PTSD, depression, anxiety, addiction and other mental health disorders. It has filed a new, full patent application covering the MYCO-006 family of novel short-acting MDMA analogs with the World Intellectual Property Organization.
The provisional patent application was done in July 2021. The family of MDMA-like compounds is intended to reduce harm and improve safety compared to MDMA, targeting a reduced duration with the same effects as traditional MDMA.
As Mydecine's chief scientific officer Rob Roscow expressed: "From Rick Ingrasc's early work in the early 70's and 80's with couples counseling, to MAPS more recent work with PTSD, MDMA has shown strong positive results removing interpersonal distrust and communication blocks without interfering with cognition. This effect allows therapy to be more effective."
Yet Roscow further clarified that "although MDMA has shown great promise, the effects of the drug last 8 or more hours which is not ideal for a traditional medical setting," which is why the company is aiming at developing healthcare treatments that may be accessible to a wider crowd.
Mydecine's chief medical officer Dr. Rakesh Jetly added: "Psychedelic-assisted psychotherapy utilizing classic MDMA can take upwards of 12 hours to complete one session and a large amount of resources. Under this model, therapists would only be able to treat 2-4 patients per month. Our hope is by decreasing the half-life of MDMA, we can create treatments that can be easily repeated at your typical healthcare facility in order to make accessible and affordable treatments for patients."
Lobe Sciences's Patents on Psilocybin And Psilocin Analogues
Life sciences psychedelics company Lobe Sciences (OTCQB:LOBEF) has filed a provisional patent that would cover the preparation and use of its stable psilocin proprietaries and analogues.
As CEO Philip Young explained, Lobe's patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin, psilocin analogues and N-Acetyl Cysteine (NAC) as well as a new patent that covers the uses and preparation of multiple proprietary stable forms of the psilocin molecule.
The company is pursuing drug development programs using two initial proprietary psilocin analogues: L-130, targeting neurological conditions such as severe anxiety, PTSD and brain traumas; and L-131, a new, psilocin-related chemical entity covered in the recently filed patent application, which is a drug candidate for a neurological disorder affecting children.
As well as drug development, Lobe is also focused on distributing non-hallucinatory doses of their therapeutics whether to patients' homes, to their physician's offices or to the emergency unit in local hospital settings.
Photo by Philipp Katzenberger on Unsplash
Mydecine (OTC:MYCOF) and Lobe Sciences (OTCQB:LOBEF), two companies in the psychedelics space, have filed patent applications. This is the first step in the process of receiving a patent, which needs to be granted by an overseeing body.
霉菌素(场外交易:MYCOF)和叶状科学(场外交易代码:LOBEF),两家迷幻药物领域的公司已经提交了专利申请。这是获得专利过程中的第一步,需要得到监督机构的批准。
Mydecine's Patent On The MYCO-006 Family Of Compounds
Mydecine公司关于myco-006系列化合物的专利
Mydecine is a company developing innovative first- and-second-generation therapeutics for the treatment of PTSD, depression, anxiety, addiction and other mental health disorders. It has filed a new, full patent application covering the MYCO-006 family of novel short-acting MDMA analogs with the World Intellectual Property Organization.
Mydecine是一家开发创新的第一代和第二代疗法的公司,用于治疗创伤后应激障碍、抑郁、焦虑、成瘾和其他精神健康障碍。该公司已提交了一项新的完整专利申请,涵盖Myco-006系列新型短效MDMA类似物世界知识产权组织。
The provisional patent application was done in July 2021. The family of MDMA-like compounds is intended to reduce harm and improve safety compared to MDMA, targeting a reduced duration with the same effects as traditional MDMA.
临时专利申请于2021年7月完成。这个MDMA类化合物家族与MDMA相比,旨在减少危害并提高安全性,目标是缩短持续时间,并具有与传统MDMA相同的效果。
As Mydecine's chief scientific officer Rob Roscow expressed: "From Rick Ingrasc's early work in the early 70's and 80's with couples counseling, to MAPS more recent work with PTSD, MDMA has shown strong positive results removing interpersonal distrust and communication blocks without interfering with cognition. This effect allows therapy to be more effective."
ASMydecine的首席科学官Rob Roscoo表示:“发件人里克·英格拉奇在70年代初和80年代初对夫妻咨询的早期工作,到最近对创伤后应激障碍的工作,MDMA在消除人际间的不信任和沟通障碍的同时,不干扰认知,显示出了很强的积极效果。这种效果让治疗变得更有效。
Yet Roscow further clarified that "although MDMA has shown great promise, the effects of the drug last 8 or more hours which is not ideal for a traditional medical setting," which is why the company is aiming at developing healthcare treatments that may be accessible to a wider crowd.
然而,罗斯考进一步澄清说:“尽管MDMA显示出了巨大的前景,但这种药物的效果持续了8个小时或更长时间,这对于传统的医疗环境来说并不理想,这就是为什么该公司的目标是开发可能对更广泛的人群可及.
Mydecine's chief medical officer Dr. Rakesh Jetly added: "Psychedelic-assisted psychotherapy utilizing classic MDMA can take upwards of 12 hours to complete one session and a large amount of resources. Under this model, therapists would only be able to treat 2-4 patients per month. Our hope is by decreasing the half-life of MDMA, we can create treatments that can be easily repeated at your typical healthcare facility in order to make accessible and affordable treatments for patients."
Mydecine的首席医疗官Rakesh Jetly博士补充道:“使用经典MDMA的迷幻药物辅助心理治疗可能需要12小时以上才能完成一次疗程和大量资源。。在这种模式下,治疗师每月只能治疗2-4名患者。我们希望通过减少MDMA的半衰期,我们可以创造出可以在你的典型医疗机构很容易重复的治疗方法,以便为患者提供可获得和负担得起的治疗。“
Lobe Sciences's Patents on Psilocybin And Psilocin Analogues
波普科学公司的P专利西洛菌素和西洛菌素类似物
Life sciences psychedelics company Lobe Sciences (OTCQB:LOBEF) has filed a provisional patent that would cover the preparation and use of its stable psilocin proprietaries and analogues.
生命科学迷幻药公司叶科学(OTCQB:LOBEF)已经提交了一项临时专利,将涵盖其稳定的裸球菌素类药物及其类似物的制备和应用.
As CEO Philip Young explained, Lobe's patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin, psilocin analogues and N-Acetyl Cysteine (NAC) as well as a new patent that covers the uses and preparation of multiple proprietary stable forms of the psilocin molecule.
AS首席执行官菲利普·杨据介绍,利普公司的专利组合现在包括裸盖菇素、裸盖菇素类似物和N-乙酰半胱氨酸(NAC)的使用和交付的多项专利申请,以及一项涵盖裸盖菇素分子多种专有稳定形式的用途和制备的新专利。
The company is pursuing drug development programs using two initial proprietary psilocin analogues: L-130, targeting neurological conditions such as severe anxiety, PTSD and brain traumas; and L-131, a new, psilocin-related chemical entity covered in the recently filed patent application, which is a drug candidate for a neurological disorder affecting children.
该公司正在使用两种最初的专有psiLocin类似物进行药物开发计划:L-130,针对严重焦虑、创伤后应激障碍和脑部创伤等神经疾病;以及L-131,一种新的与psiLocin相关的化学实体,在最近提交的专利申请中涵盖,这是一种治疗影响儿童的神经疾病的候选药物。
As well as drug development, Lobe is also focused on distributing non-hallucinatory doses of their therapeutics whether to patients' homes, to their physician's offices or to the emergency unit in local hospital settings.
除了药物开发,LOPE还专注于分发他们治疗药物的非幻觉剂量无论是到病人家中,到他们的医生办公室,还是到当地医院的急诊室。
Photo by Philipp Katzenberger on Unsplash
图片由Philipp Katzenberger在Unspash上拍摄
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧